Bladder Cancer Detection Kits - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bladder cancer detection kits market size is projected to be USD 0.98 billion in 2025, USD 1.08 billion in 2026, and reach USD 1.67 billion by 2031, growing at a CAGR of 9.25% from 2026 to 2031. This report is Segmented by Product Type (Urine-Based, Blood-Based, Tissue-Based, Other), Technology (FISH, Immunoassay, Molecular Diagnostic, DNA Methylation and RNA Signature, Other), End User (Hospitals and Urology Clinics, Diagnostic Labs, Cancer Research Institutes, Other), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts are Provided in Terms of Value (USD).

Global Bladder Cancer Detection Kits Market Trends and Insights

Rising Bladder Cancer Surveillance Burden

The bladder cancer detection kits market is benefiting from a larger surveillance population because bladder cancer cases in adults aged 55 and older rose from 226,421 to 483,234 over the past three decades. This matters because older patients form the highest-risk group and remain the core population for repeated evaluation after diagnosis and treatment. Recurrence also keeps testing volumes elevated, since each NMIBC patient faces a lifetime average of 6.6 recurrences, which creates repeated monitoring demand even when new diagnosis growth slows. High-income regions in North America and Western Europe still carry the heaviest incidence burden, which supports steady utilization in markets with stronger reimbursement and laboratory capacity. China adds another durable volume base to the bladder cancer detection kits market, with male incidence projected to rise from 9.1 per 100,000 in 2021 to 11.2 per 100,000 by 2035.

Shift Toward Non-Invasive Urine-Based Testing

The bladder cancer detection kits market gained a clear clinical tailwind in 2025 when the AUA endorsed urinary biomarker tumor markers as an option for intermediate-risk microscopic hematuria patients who prefer to defer cystoscopy. That recommendation matters because a negative urinary biomarker result can reduce cancer probability for these patients from 0.2-3.1% to 0.1-0.4%, which changes the clinical path for a meaningful part of the workup population. The UroFollow trial also showed that urine markers combined with ultrasound can support a clinically non-inferior surveillance alternative to white-light cystoscopy in low- and intermediate-risk NMIBC patients. Technical performance has improved enough to support this shift, with multitarget urine DNA tests reporting 91.37% sensitivity, 95.09% specificity, and 0.9583 AUC in double-blinded multicenter prospective testing. As more decisions move from bundled cystoscopy encounters to separately ordered urine tests, the bladder cancer detection kits market is gaining a broader commercial base for standalone kit suppliers and centralized laboratories.

Persistent Dependence on Cystoscopy as Diagnostic Anchor

The bladder cancer detection kits market still faces a structural ceiling because the 2025 EAU NMIBC Guidelines state that flexible cystoscopy cannot be replaced by cytology or any other non-invasive test in routine surveillance. That position reflects continued concern over missed detection in patients with multifocal disease or high-grade lesions, where negative predictive value remains under pressure at higher pre-test risk. The commercial effect is that urine markers are often adopted as adjuncts rather than as true substitutes, which limits how much cystoscopy spending can move into kit-based testing. Existing surveillance practice also reinforces itself, because high cystoscopy volumes keep the endoscopic visit at the center of follow-up care and make change slower even when supporting biomarker data improve. The UroFollow trial is important in this setting because it is one of the strongest efforts to produce randomized evidence that could shift future surveillance pathways.

Other drivers and restraints analyzed in the detailed report include:

• AI-Assisted Risk Stratification in Hematuria Workups
• Reimbursement Support for Adjunctive Urothelial Tests
• Limited Clinical Standardization Across Biomarker Panels

Segment Analysis

Urine-Based Detection Kits held 52.31% of product-type revenue in 2025, giving them the largest share in the bladder cancer detection kits market. Their leading position reflects how closely urine sampling fits the disease biology, since bladder tumors shed cells and biomarkers directly into urine during routine voiding. That specimen advantage gives urine assays a practical role across initial hematuria workups, NMIBC recurrence surveillance, and follow-up after treatment. Tissue-based kits still retain a narrower but stable role in histological confirmation and post-TURBT assessment, while lower-complexity strip formats keep a point-of-care presence in settings with limited molecular laboratory access.

Blood-Based Detection Kits are projected to grow at an 11.38% CAGR from 2026 to 2031, making them the fastest-growing product segment in the bladder cancer detection kits industry. BIOSPACE The growth step changed in May 2026, when the FDA approved Signatera CDx together with Tecentriq for ctDNA MRD-guided adjuvant treatment in post-cystectomy MIBC patients. That decision created oncologist-led blood test demand that is distinct from the urologist-led urine surveillance pathway in NMIBC. The product mix in the bladder cancer detection kits market is therefore becoming broader rather than shifting away from urine, because the two formats are serving different disease stages and clinical decisions.

Complete Report Scope:

• By Product Type
  • Urine-Based Detection Kits
  • Blood-Based Detection Kits
  • Tissue-Based Detection Kits
  • Other Product Types
• By Technology
  • Fluorescence In Situ Hybridization Kits
  • Immunoassay Kits
  • Molecular Diagnostic Kits
  • DNA Methylation and RNA Signature Kits
  • Other Technologies
• By End User
  • Hospitals and Urology Clinics
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.22% of the bladder cancer detection kits market share in 2025 and remains the most established regional base for adjunctive bladder cancer biomarker testing. The region benefits from a dense network of CLIA-certified laboratories, high urologist encounter volumes, and payer structures that can absorb new tests once coverage and coding become clear. The United States drives most of that demand because reimbursement decisions there can quickly widen or narrow access to specific assay formats. The May 2026 approval of Tecentriq with Signatera CDx adds a new commercial path in North America by linking blood-based MRD testing to a defined post-cystectomy treatment decision in muscle-invasive disease.

Europe remains a significant regional pillar in the bladder cancer detection kits market, with Germany standing out for evidence generation and laboratory readiness. The UroFollow trial was conducted across German centers, which shows that the region has the clinical infrastructure needed to test marker-guided surveillance pathways in routine practice. Europe also shapes adoption through guideline influence, since EAU recommendations continue to define how urine markers are used against cystoscopy in NMIBC follow-up. This keeps the region commercially important both as a demand center and as a proving ground for evidence that can support broader payer acceptance later.

Asia-Pacific is the fastest-growing region in the bladder cancer detection kits market and is projected to expand at an 11.65% CAGR through 2031. China is central to that trajectory because it carried 45,114 deaths and 570,636 prevalent bladder cancer cases in 2021, while male incidence is still projected to rise through 2035. The April 2025 launch of China’s first dual methylation-plus-gene-mutation urothelial carcinoma detection product shows that local development is beginning to move alongside local disease burden. Japan adds another layer of demand because its aging population supports recurring surveillance needs and creates a stable patient base for follow-up testing. South America and the Middle East and Africa remain smaller opportunity pools, but the pace of expansion there is still limited by weaker access to centralized molecular laboratories outside major urban centers.

List of Companies Covered in this Report:

• Abbott Laboratories
• Beckton Dickinson
• Beckton Dickinson
• Bio-Rad Laboratories
• Cancer Diagnostics, Inc.
• Cxbladder / Pacific Edge Limited
• Danaher
• Exact Sciences
• Roche
• Hologic
• NanoString Technologies
• Nonagen Bioscience, Inc.
• Photocure ASA
• QIAGEN
• Siemens Healthineers
• Sysmex
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support